Abstract
Introduction
Cardiac troponin I (cTnI) has been used clinically, for years, for diagnosis and risk stratification in patients with suspected acute myocardial infarction (AMI)1. Generally, elevated levels of cTns are conjoined with damage of cardiac muscles and cTnI release to the circulation has specificity for cardiac injury2. Measurement of circulating levels cTnI, particularly observing the rise or fall in cTnI levels, along with the evaluation of patient symptoms, history and electrocardiographic (ECG) abnormalities are current procedures in the triage of suspected AMI patients3,4. The typical challenge is early identification of AMI among the large heterogenous patient population, as only one in three patients, experiencing chest pain, who visit emergency department (ED) receives AMI diagnosis5. Therefore, timely and correct diagnosis to rule-in AMI is important in terms of cost savings and improving the clinical outcomes of AMI patients.
Point-of-care testing (POCT) can facilitate quick turn-around-times (TAT) to promote efficient diagnosis of AMI6. Lateral flow immunoassays (LFIAs) can be used in POCT, particularly in settings where the cost of the high-tech instrumentation may be prohibitive. LFIA in POCT is well-established, mature technology known for its low cost. However, the limitations regarding sensitivity and quantification have hindered its use in many applications7. In our previous work, we have described how the use of upconverting nanoparticle (UCNP) reporters in LFIAs provides quantitative results and improved sensitivity8,9,10.
The use of UCNP measurement technology can enhance the assay sensitivity in comparison to traditional down-converting fluorescent reporters since it enables elimination of the background autofluorescence from the measurement. This is due to the unique photon upconversion luminescence of UCNP reporters converting low-energy excitation (near or at infrared) wavelength into high-energy emission at visible wavelengths11. The UCNP signal can be read with a miniaturized relatively low-cost reader instruments with high performance in POCT settings. Such readers with miniaturized optics for UCNP measurement have previously been described in the literature12,13,14,15.
The performance of LFIAs may suffer from interferences originating from the sample matrix, particularly because of the typical one or two step assay procedure with limited washing. These immunoassay (IA) interferences may be caused by different interfering agents such as circulating heterophilic IgG and IgM antibodies16, autoantibodies targeted against the biomarker of interest17 and human anti-animal antibodies18. In general, IgG antibodies used as binders in IAs are prone to several interfering reactions caused by circulating antibodies.

If a heterophilic antibody has high affinity for the Fc-region of an IA binder antibodies, an aggregate of binder antibodies with large numbers of Fc-regions close together functions as a binding target for the heterophilic antibody16. Furthermore, it has been shown that complement activation by the classical pathway can occur when several IgG molecules are in close proximity, e.g. on reporter nanoparticle surface19 or on the solid phase20. As a results, complement factors bind to the Fc region of the IA binder antibody20,21 which causes negative interference in the IA. Non-specific binding of autoantibodies such as rheumatoid factor (RF) has been associated with falsely elevated analyte concentrations22. Since IAs utilizing nanoparticle reporters aim at extremely high sensitivities, the effect of matrix interferences should be addressed to fully utilize the potential of nanoparticle IA technologies.
It has been depicted that the effects of interfering agents can be eliminated with sample pre-treatment procedures such as heating or precipitation of interfering antibodies with polyethylene glycol (PEG)20. In addition, pretreatment with Ethylenediamine tetra-acetic acid (EDTA) effectively inhibits the activation of the complement pathway23. However, particularly in the case of POCT, time-consuming sample pre-treatment steps are undesirable. Therefore, in LFIAs the potential solutions should be implemented in the test device itself.
In this study, we report the development of a UCNP-LFIA for cTnI. UCNP reporter technology was utilized to provide the sensitive and quantitative detection of cTnI in LFIA format to overcome the typical limitations of LFIAs. The matrix interference in plasma samples was studied and reduced by incorporating the developed sample pre-treatment steps into the LF strip. The performance of the developed UCNP-LFIA was evaluated with clinical plasma samples (n = 262).
Adiponectin (mouse) Elisa Assay Kit |
|||
K4902-100 | Biovision | each | EUR 1038 |
Adiponectin (rat) Elisa Assay Kit |
|||
K4903-100 | Biovision | each | EUR 1011.6 |
Visfatin (human) Elisa Assay Kit |
|||
K4907-100 | Biovision | each | EUR 1182 |
XTT CELL VIABILITY ASSAY KIT (1000 ASSAY) |
|||
30007 | Biotium | 1KIT | EUR 283.2 |
Description: Minimum order quantity: 1 unit of 1KIT |
Feline SAA Detection ELISA Assay Kit |
|||
6028 | Chondrex | 1 kit | EUR 663.78 |
Description: Feline SAA Detection ELISA Assay Kit |
Endothelial Tube Formation Assay (In Vitro Angiogenesis Assay) |
|||
CBA-200 | Cell Biolabs | 50 assays | EUR 672 |
Description: For angiogenesis to occur, endothelial cells must escape their stable location and break through the basement membrane. Cells migrate toward an angiogenic stimulus that may be released from nearby tumor cells. These cells proliferate to form new blood vessels. Our Endothelial Tube Formation Assay (In Vitro Angiogenesis) provides an easy, robust system to assess angiogenesis in vitro. The ECM gel matrix very closely resembles an in vivo environment. |
Proteasome Assay Kit |
|||
55R-1341 | Fitzgerald | 100 assays | EUR 784.8 |
Description: Assay Kit for detection of Proteasome in the research laboratory |
Calpain Assay Kit |
|||
55R-1342 | Fitzgerald | 100 assays | EUR 934.8 |
Description: Assay Kit for detection of Calpain in the research laboratory |
Glutathione Assay Kit |
|||
55R-1343 | Fitzgerald | 100 assays | EUR 784.8 |
Description: Assay Kit for detection of Glutathione in the research laboratory |
Glutathione Assay Kit |
|||
55R-1354 | Fitzgerald | 100 assays | EUR 1074 |
Description: Assay Kit for detection of Glutathione activity in the research laboratory |
HDAC Assay Kit |
|||
55R-1371 | Fitzgerald | 100 assays | EUR 807.6 |
Description: Assay Kit for detection of HDAC in the research laboratory |
HDAC Assay Kit |
|||
55R-1372 | Fitzgerald | 100 assays | EUR 807.6 |
Description: Assay Kit for detection of HDAC in the research laboratory |
HAT Assay Kit |
|||
55R-1373 | Fitzgerald | 100 assays | EUR 888 |
Description: Assay Kit for detection of HAT in the research laboratory |
SOD Assay Kit |
|||
55R-1374 | Fitzgerald | 100 assays | EUR 722.4 |
Description: Assay Kit for detection of SOD in the research laboratory |
HDAC3 Assay Kit |
|||
55R-1377 | Fitzgerald | 100 assays | EUR 831.6 |
Description: Assay Kit for detection of HDAC3 in the research laboratory |
HDAC8 Assay Kit |
|||
55R-1379 | Fitzgerald | 100 assays | EUR 826.8 |
Description: Assay Kit for detection of HDAC8 in the research laboratory |
ATP Assay Kit |
|||
55R-1380 | Fitzgerald | 100 assays | EUR 970.8 |
Description: Assay Kit for detection of ATP in the research laboratory |
ADP Assay Kit |
|||
55R-1381 | Fitzgerald | 100 assays | EUR 970.8 |
Description: Assay Kit for detection of ADP in the research laboratory |
FAD Assay Kit |
|||
55R-1382 | Fitzgerald | 100 assays | EUR 878.4 |
Description: Assay Kit for detection of FAD in the research laboratory |
PEP Assay Kit |
|||
55R-1384 | Fitzgerald | 100 assays | EUR 1051.2 |
Description: Assay Kit for detection of PEP in the research laboratory |
Ammonia Assay Kit |
|||
55R-1388 | Fitzgerald | 100 assays | EUR 888 |
Description: Assay Kit for detection of Ammonia in the research laboratory |
cAMP Assay Kit |
|||
55R-1389 | Fitzgerald | 100 assays | EUR 847.2 |
Description: Assay Kit for detection of cAMP activity in the research laboratory |
cGMP Assay Kit |
|||
55R-1390 | Fitzgerald | 100 assays | EUR 847.2 |
Description: Assay Kit for detection of cGMP activity in the research laboratory |
Urea Assay Kit |
|||
55R-1391 | Fitzgerald | 100 assays | EUR 888 |
Description: Assay Kit for detection of Urea in the research laboratory |
Calcium Assay Kit |
|||
55R-1392 | Fitzgerald | 250 assays | EUR 703.2 |
Description: Assay Kit for detection of Calcium activity in the research laboratory |